- Expands Staff to Continue Record of Investment Success -
GAITHERSBURG, Md., Jan. 7 /PRNewswire/ -- MedImmune, the operationally independent worldwide biologics unit of AstraZeneca plc (LSE: AZN.L, NYSE: AZN), today announced that its highly successful venture capital fund, MedImmune Ventures, will broaden its focus to include areas of strategic interest to both organizations by adding the therapeutic areas of cardiovascular and metabolic disease, pain and central nervous system disorders and gastrointestinal disease. Traditionally, MedImmune Ventures has focused its efforts on the areas of infectious disease, oncology and inflammatory disease. Since its inception in 2002, MedImmune Ventures has invested in 22 companies.
"We look forward to making meaningful investments in these additional therapeutic areas," said Edward T. Mathers, executive vice president, corporate development and venture, MedImmune. "Now that we are more fully aligned with AstraZeneca's core areas of interest, we are able to help both MedImmune and AstraZeneca to stay at the forefront of novel science with a direct window to the most innovative start-ups in the biotechnology industry."
Mr. Mathers and MedImmune President & CEO David M. Mott currently lead
MedImmune Ventures. To accommodate the broader disease area focus,
MedImmune Ventures has added Maggie Flanagan LeFlore, Ph.D. and Eva M. Jack
as managing directors to its team of experts that oversee the assessment of
all new investment opportunities. Previously, Dr. LeFlore was on assignment
from AstraZeneca to the healthcare and life science venture investment team
at Advent International, and Ms. Jack was director, business development at
MedImmune. Also, Joseph L. Amprey, M.D., Ph.D. was promoted to managing
director of MedImmune Ventures following the June 2007 retirement of its
president, Wayne T. Hockmeyer, Ph.D. Franklin H. Top, M.D., who has been
with MedImmune since 1988 and is the company's former m
Copyright©2008 PR Newswire.
All rights reserved